ArticleFrontiers in bioinformatics2026
In silico transcriptomic analysis nominates TSPAN32 as a central node of SCFA-driven immunometabolic reprogramming in intestinal epithelial cells.
Article in Frontiers in bioinformatics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Microbial short-chain fatty acids (SCFAs) regulate intestinal epithelial homeostasis and immune tolerance. Yet, the specific host effector genes that mediate these responses remain poorly defined, limiting the identification of biomarkers and therapeutic targets. Methods: A multi-layered Results: Under FDR correction, TSPAN32 emerged as the sole transcriptome-wide significant gene following SCFA exposure (log Conclusion: These hypothesis-generating findings nominate TSPAN32 as the primary SCFA-responsive effector gene in intestinal epithelial cells, coordinating epigenetic remodeling and immunometabolic reprogramming. Causal validation through functional perturbation and independent cohort replication is required before clinical translation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.